Evidence map›Paper›PMID 29149865›Full record

Trial reportBMC cancer2017

Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial.

Baki Topal, Karel Demey, Halit Topal, Joris Jaekers, Eric Van Cutsem, Vincent Vandecaveye, Xavier Sagaert, Hans Prenen

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01116791 (Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01116791 phase2terminatednot on this map

Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial

TypeinterventionalSponsorBaki TopalRan2010 to 2015Enrolled34ConditionsPeritoneal Carcinomatosis, Gastrointestinal CancerArmsCytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review.International journal of environmental research and public health · 2022
    Review
  6. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021
    Review
  7. Surgical management of metastatic gastric cancer: moving beyond the guidelines.Translational gastroenterology and hepatology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Baki TopalDepartment of Abdominal Surgical Oncology, University Hospitals KU Leuven, Herestraat 49, 3000, Leuven, Belgium. baki.topal@uzleuven.be.ORCID http://orcid.org/0000-0002-2687-7535
Karel DemeyDepartment of Abdominal Surgical Oncology, University Hospitals KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Halit TopalDepartment of Abdominal Surgical Oncology, University Hospitals KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Joris JaekersDepartment of Abdominal Surgical Oncology, University Hospitals KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Eric Van CutsemDepartment of Digestive Oncology, University Hospitals KU Leuven, Leuven, Belgium.
Vincent VandecaveyeDepartment of Radiology, University Hospitals KU Leuven, Leuven, Belgium.
Xavier SagaertDepartment of Pathology, University Hospitals KU Leuven, Leuven, Belgium.
Hans PrenenDepartment of Digestive Oncology, University Hospitals KU Leuven, Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytoreductive surgery (CRS) plus hyperthermic intra-operative peritoneal chemotherapy (HIPC) for gastric peritoneal carcinomatosis (PC) is controversial, and selection criteria for this treatment modality are lacking.

methodsThirty-two patients (F/M ratio 12/20; median (range) age 58 (32-75) years) underwent CRS + HIPC with cisplatin for PC from gastric adenocarcinoma in 2010-2014. This monocentric phase-2 nonrandomized prospective study with a power of 90% aimed to improve the 1-year overall survival (OS) rate with 40% (historical reference of 52% to 72%). Median PCI score was 8 (range 1-20), number of regions involved was 6 (range 1-11). The impact of 16 prognostic factors on survival was evaluated using univariable and multivariable Cox regression models. Follow-up was complete in all patients, and closed 2 years after patient inclusion.

resultsAll patients had complete cytoreduction (CCR-0) and histopathological R0 resection. PCI </= 12 without PC on any small bowel region with 4 or more non-small bowel regions resulted in a median OS time of 24.7 months (15.6-29.4), and 1, 2, 5-year OS rates of 90%, 55%, 5.6%, respectively. Independent predictors of OS were PC on the small bowel combined with PC on 4 or more non-small bowel regions (p = 0.0004), number of regions involved (p = 0.0029), and overall PCI score (p = 0.0104).

conclusionsCRS + HIPC with cisplatin to treat gastric PC, providing complete cytoreduction and R0 resection, should be restricted to patients with PCI of 12 or less. Patients having PC on any small bowel region with 4 or more non-small bowel regions should be refused for CRS + HIPC. TRIAL REGISTRATION NUMBER: Registration number: NCT01116791 . Registration date: May 5, 2010.

Indexed as

Cytoreduction Surgical ProceduresHyperthermia, InducedAdultAgedAntineoplastic AgentsCarcinomaCisplatinCombined Modality TherapyFemaleHumansIntraoperative CareMaleMiddle AgedPeritoneal NeoplasmsPrognosisProportional Hazards ModelsAntineoplastic AgentsCisplatin

Identifiers

PMID29149865
PMCPMC5693494
OpenAlexW2768564752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.